Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia-Reference-Cited by-同舟云学术

Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia

Published:2018-01-05 Issue:4 Volume:283 Page:371-379
ISSN:0954-6820
Container-title:Journal of Internal Medicine
language:en
Short-container-title:J Intern Med

Author:

Craddock C.¹^ORCID,Versluis J.²,Labopin M.³,Socie G.⁴,Huynh A.⁵,Deconinck E.⁶,Volin L.⁷,Milpied N.⁸,Bourhis J. H.⁹,Rambaldi A.¹⁰,Chevallier P.⁸,Blaise D.¹¹,Manz M.¹²,Vellenga E.¹³,Vekemans M-C.¹⁴,Maertens J.¹⁵,Passweg J.¹⁶,Vyas P.¹⁷,Schmid C.¹⁸,Löwenberg B.²,Ossenkoppele G.¹⁹,Mohty M.²⁰,Cornelissen J. J.²,Nagler A.²¹²²,

Affiliation:

1. Centre for Clinical Haematology; Queen Elizabeth Hospital; Birmingham UK

2. Department of Hematology; Erasmus University Medical Center Cancer Institute; Rotterdam The Netherlands

3. Department of Haematology; Hospital Saint Antoine; Paris France

4. Department of Hematology; Hospital Saint-Louis; Sorbonne University; Paris France

5. Department of Haematology; CHU; Toulouse France

6. Department of Hematology; CHU; Besancon France

7. Stem Cell Transplantation Unit; HUCH Comprehensive Cancer Center; Helsinki Finland

8. Department of Hamatology; CHU; Nantes France

9. Department of Medical Oncology; Institute of Cancer; Villejuif France

10. Department of Hematology; University of Milan; Milan Italy

11. Department of Hematology; Centre of Cancer Research; Marseille France

12. Center for Hemato-Oncology; University Hospital Zurich; Zurich Switzerland

13. Department of Hematology; University Medical Center Groningen; Groningen The Netherlands

14. Department of Hematology; Saint-Luc University; Brussels Belgium

15. Department of Haematology; University Hospital Gasthuisberg; Leuven Belgium

16. Department of Haematology; University of Basel; Basel Switzerland

17. Weatherall Institute of Molecular Medicine; University of Oxford; Oxford UK

18. Stem Cell Transplantation Unit; Department of Medicine; University of Munich; Munich Germany

19. Department of Haematology; University Medical Center; Amsterdam The Netherlands

20. Hospital Saint-Antoine; University UPMC; Paris France

21. Chaim Sheba Medical Center; Tel Aviv University; Tel Aviv Israel

22. ALWP office of the EBMT Hospital Saint Antoine; Paris France

Publisher

Wiley

Subject

Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/joim.12720/fullpdf

Reference26 articles.

1. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT;Tsirigotis;Bone Marrow Transplant,2016

2. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet;Dohner;Blood,2010

3. The European LeukemiaNet AML working party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach;Cornelissen;Nat Rev Clin Oncol,2012

4. Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia;Ossenkoppele;Haematologica,2016

5. Genomic classification in acute myeloid leukemia;Papaemmanuil;N Engl J Med,2016

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FLT3 is genetically essential for ITD-mutated leukemic stem cells but dispensable for human hematopoietic stem cells;2024-07-02

2. Survival after allogeneic transplantation according to pretransplant minimal residual disease and conditioning intensity in patients with acute myeloid leukemia;Frontiers in Oncology;2024-05-02

3. Late Relapse after Allogeneic Stem Cell Transplantation in Patients Treated for Acute Myeloid Leukemia: Relapse Incidence, Characteristics, Role of Conditioning Regimen, and Outcome;Cancers;2024-04-05

4. Refractory patients with favorable/intermediate‐risk acute myeloid leukemia benefit from azacytidine maintenance therapy following allogeneic hematopoietic stem cell transplantation;Hematological Oncology;2023-10-04

5. Azacitidine and lenalidomide combination: a novel relapse prophylaxis regimen after allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia;Frontiers in Immunology;2023-06-22